



**MAXIM Group Resumes Coverage on SINTX Technologies with Buy Rating and \$6 Price Target**

June 4, 2026

**MAXIM Group Resumes Coverage on SINTX Technologies with Buy Rating and \$6 Price Target**

Independent analyst coverage highlights SINTX's progress toward becoming a diversified silicon nitride biomaterials platform company, citing the company's FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, expanding commercialization strategy, and opportunities across orthopedic, antipathogenic, and patient-specific implant applications. The report also notes SINTX's proprietary manufacturing capabilities, 3D-printing initiatives, and silicon nitride technology platform as potential drivers of future growth.



**Analyst Coverage**

▲SINT SINT

June 2026

**Buy**



**\$6 Price Target ↑**